Drug Type T cell antigen coupler-T cells |
Synonyms TAC201-Claudin18.2 (Allo), TAC 201 (Triumvira), TAC201 (Triumvira) + [1] |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization Triumvira Immunologics, Inc.Startup |
Active Organization Triumvira Immunologics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Adenocarcinoma | Preclinical | US | Triumvira Immunologics, Inc.Startup | 25 Apr 2024 |
Stomach Cancer | Preclinical | US | Triumvira Immunologics, Inc.Startup | 25 Apr 2024 |